#Canada #London #Alimentiv #IBUS #IUS-STAR

Strengthening Gastrointestinal Research: The IUS-STAR Initiative

In a significant development for the field of gastrointestinal research, Alimentiv Inc. has announced an expansion of its partnership with the International Bowel Ultrasound Group (IBUS) to include a transformative training program designed for clinical trials. Officially dubbed the IUS Standardized Training and Acquisition for Research (IUS-STAR) Certificate, this initiative aims to equip ultrasound professionals with cutting-edge skills necessary for conducting high-quality intestinal ultrasound (IUS) assessments within clinical settings.

Enhancing Quality in Clinical Trials

The IUS-STAR program is tailored specifically for sonographers, radiologists, and medical technicians who play pivotal roles in clinical trial imaging. By combining e-learning with practical, hands-on scanning techniques and rigorous image review processes, the program provides operators with insightful feedback, refining their capabilities to produce protocol-compliant imaging.

Alimentiv's Chief Operations Officer, Stephanie Gonzalez, emphasizes that this innovative approach not only enhances operational efficiency but also ensures that sponsors can mobilize qualified ultrasound technicians rapidly across clinical sites. "IUS-STAR reflects what this partnership does best. It pairs IBUS’s scientific leadership with our robust global infrastructure, including the Notō Case Manager technology for comprehensive image review and quality oversight," Gonzalez stated. She underscored that this collaboration enhances site readiness, enabling faster set-ups and a broader network of IUS-trained sites for inflammatory bowel disease (IBD) trials.

Impacts on Patient Participation and Care

The historical context of this initiative can be traced back to the exclusive partnership between Alimentiv and IBUS formed in 2022, which sought to integrate leading IUS methodologies into clinical trial environments across over 34 countries. Since then, the strategic application of intestinal ultrasound has significantly advanced the field of IBD research by providing non-invasive imaging alternatives that enhance patient monitoring.

IBUS President Kerri Novak highlights the critical role of ultrasound tools in clinical trials, particularly for identifying patients suffering from active disease. The IUS technology not only makes participation in clinical trials more accessible to patients but also holds the potential to deepen understanding of disease processes and response to treatment. "Our initiative aims to elevate the caliber of ultrasound images obtained during trials, ensuring consistency and quality that align with patient safety and optimal outcomes," Novak mentioned.

Looking Ahead: Advancing Research and Innovation

As the demand for non-invasive disease monitoring tools grows, Alimentiv and IBUS are dedicated to fostering an educational ecosystem that promotes innovation and standardization in IUS practices. The launch of the IUS-STAR program represents a significant leap forward in supporting clinical trial operations, researchers, and health care professionals committed to improving the lives of patients burdened by gastrointestinal conditions.

For professionals keen on enhancing their capabilities, further information about the IUS-STAR program is available through direct contact with Alimentiv. This collaborative effort symbolizes a promising advancement in the synergy between medical imaging and clinical research, focusing on healthier outcomes for patients worldwide.

For more details, professionals can reach out at [email protected].

About Alimentiv

With over 30 years in the field, Alimentiv is a leading global contract research organization (CRO) specialized in gastrointestinal clinical trials. Operating under a framework of precision medicine, Alimentiv collaborates with pharmaceutical and biotechnology companies, advancing innovative therapies aimed at improving treatment outcomes for GI disease patients. The company operates an expansive service network in Canada, the United States, Europe, Asia-Pacific, and Latin America, underscoring its global commitment to enhancing gastrointestinal healthcare.

About IBUS

The International Bowel Ultrasound Group (IBUS) is a not-for-profit organization dedicated to promoting intestinal ultrasound's use in clinical investigations and education related to inflammatory bowel disease (IBD). The group has established itself as a key player in global discussions regarding IUS education, research collaborations, and the implications of this innovative imaging modality on patient care. For additional insights into IBUS's initiatives, visit ibus-group.org.